Bank of America Forecasts Strong Price Appreciation for Keros Therapeutics (NASDAQ:KROS) Stock

Keros Therapeutics (NASDAQ:KROS) had its target price upped by research analysts at Bank of America from $18.00 to $19.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Bank of America‘s target price indicates a potential upside of 8.57% from the company’s current price.

KROS has been the subject of a number of other reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of Keros Therapeutics in a research report on Monday, November 24th. Zacks Research raised Keros Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 7th. HC Wainwright cut their target price on shares of Keros Therapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Wedbush lifted their target price on Keros Therapeutics from $15.00 to $16.00 and gave the stock a “neutral” rating in a report on Thursday, November 6th. Finally, Wells Fargo & Company decreased their price objective on Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating for the company in a research report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Keros Therapeutics currently has an average rating of “Hold” and an average target price of $30.33.

Keros Therapeutics Price Performance

KROS stock opened at $17.50 on Friday. The company has a 50 day moving average price of $15.98 and a 200 day moving average price of $14.96. Keros Therapeutics has a fifty-two week low of $9.12 and a fifty-two week high of $72.37. The stock has a market capitalization of $533.23 million, a PE ratio of 11.36, a price-to-earnings-growth ratio of 0.39 and a beta of 1.12.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.93. The firm had revenue of $14.26 million for the quarter, compared to analyst estimates of $4.22 million. Keros Therapeutics had a return on equity of 9.51% and a net margin of 26.12%.The business’s quarterly revenue was up 3585.6% compared to the same quarter last year. During the same period last year, the company earned ($1.41) EPS. As a group, equities analysts expect that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Insider Activity

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the firm’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total value of $95,659,436.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the business’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total value of $84,975,125.25. The SEC filing for this sale provides additional information. 20.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Keros Therapeutics

Several large investors have recently made changes to their positions in KROS. CWM LLC increased its holdings in Keros Therapeutics by 10,157.7% during the first quarter. CWM LLC now owns 2,667 shares of the company’s stock worth $27,000 after buying an additional 2,641 shares during the last quarter. Federated Hermes Inc. increased its stake in shares of Keros Therapeutics by 882.3% during the 1st quarter. Federated Hermes Inc. now owns 1,224,139 shares of the company’s stock worth $12,474,000 after purchasing an additional 1,099,519 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Keros Therapeutics during the 1st quarter worth about $490,000. Vanguard Group Inc. raised its holdings in shares of Keros Therapeutics by 31.1% in the 1st quarter. Vanguard Group Inc. now owns 2,566,321 shares of the company’s stock valued at $26,151,000 after purchasing an additional 609,212 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in Keros Therapeutics by 339.5% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 128,103 shares of the company’s stock valued at $1,305,000 after purchasing an additional 98,957 shares during the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.